Molecular Biomarker Antibodies Detection Technology for Lung Cancer

VITAE Biomedical is a molecular screening technology company focused on innovation and leading, providing the most valuable molecular screening technology for cancer and other diseases. In the future, not only will an integrated technology platform be established, but also an intelligent analysis system will be introduced. We provide faster, more accurate, cheaper, and more convenient automated screening systems for all medical institutions and citizens of Taiwan, which will not only detect diseases earlier and improve the survival rate of treatment, it can also help patients keep track of their healthy status after surgery. To improve the health of the Taiwanese people and enhance the quality of life of all mankind is the most important aims of us.

Recently, lung cancer can only be screened by medical image technology such as X-ray and CT (LDCT), and confirmed by the biopsy. The screening module developed by VITAE biomedical Co., Ltd. is the only lung cancer test method that can be detected by biomolecular markers.

1. The screening module developed by VITAE biomedical Co., Ltd. is the only lung cancer test method that can be detected by biomolecular markers and is suitable for early lung cancer screening, greatly improving the survival rate of lung cancer patients.
2. The usage of urine as the specimen is not only non-invasive, but also eliminates the radiation exposure problem.

 Booth No. L802